Charles Theuer

Charles Theuer (chief executive) discloses dealings in 2 companies, chiefly Tracon Pharmaceuticals, Inc. and 4D Molecular Therapeutics, Inc. We count 25 filings; the first trade dates from 21 January 2016 and the latest from 12 December 2025.

No open-market sale appears; the market trades are 22 purchases worth €196k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 2 share grants and 1 option exercise.

In size, the median ticket on the buying side is €8,991. Clusters matter here: 16 out of 22 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The record was last updated on 16 December 2025 with an option exercise (€9,063) in 4D Molecular Therapeutics, Inc. The last purchase on record was published on 28 April 2023, which is 1,269 days ago. Typically, a trade is published a median of 3 days after it takes place. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.